Webinar: DRUGS DEVELOPMENT STRATEGIES

Sponsored by: Thomson Reuters

Focused on:

    Date: 22rd September

    Days old: 4885

    Time: London 3PM / New York 10AM

    Watch Now for FREE

    Maximising the Value of Pharmaceutical Assets

    Increased pipeline attrition coupled with increased R&D spending means that R&D within Pharmaceutical companies is becoming ever increasingly unproductive. The current late-stage R&D failure rate is unsustainable: Many drugs that have passed stringent early-stage safety tests fail from lack of efficacy in Phase II/III. In light of this, Pharmaceutical companies need to target novel R&D strategies to maximize the value of R&D assets.

    In this first webinar of a two-part series, we explore strategies being used by Pharmaceutical companies to enhance pipeline value. These strategies include orphan/rare disease targeting, portfolio management strategies, patient stratification strategies, repurposing and risk sharing arrangements or financing deals. We will visit each of these strategies in turn, providing data supporting their use and evidence for their success. Through the reduction in development times, costs or risk, we describe the ways in which these strategies enhance asset value. We suggest how the increasing numbers of failed drugs within the Pharmaceutical industry might be used to companies’ advantages by repurposing and we suggest ways to prevent the disconnect between known biological targets and pathways in order to increase pipeline success.

    In a second follow on webinar, we will discuss how to turn the strategic imperatives presented in the first webinar into R&D projects.

    To register for the next webinar in this series please use the following link:

    http://business-review-webinars.com/webinar.php?c=ls&id=2ac594b9315420c665fd66fc374d53d9

    Presented by

    Hans Poulsen,

    Head of Consulting, Thomson Reuters Life Sciences Consulting Team

    Hans has over 14 years' experience consulting to the pharmaceutical, life sciences and healthcare sectors. Hans started his career as a Project Manager with DataEdge, where he developed a number of industry leading performance benchmarking databases of clinical protocol and investigator performance. Hans then joined Accenture's Global Health & Life Sciences practice where he focused on growth & innovation, new product development, and strategic and operational R&D topics with the global pharmaceutical industry. Hans holds a B.Sc. in Economics & Business Administration and an MBA in Finance

    John Arrowsmith,

    Senior Scientist, Thomson Reuters Life Sciences Consulting Team

    Dr. John Arrowsmith has over 30 years' experience in biopharmaceutical R&D with Pfizer in the UK, US and Japan. His expertise includes drug discovery and development, intellectual property, licensing, competitive intelligence, project management excellence, portfolio information systems, portfolio prioritization, continuous improvement processes, performance measures and scorecards. Author/contributor to numerous publications and patents, and co-inventor of Tikosyn®. John is a medicinal chemist by training, with a PhD. in synthetic organic chemistry and a B.Sc. in chemistry.

    Dr. Kiran Meekings,

    Consultant within the Thomson Reuters Life Sciences Consulting Team

    Kiran has over 7 years’ experience in the life sciences sector, Kiran has a broad background encompassing clinical and scientific research, pharmaceutical equity research (Merrill Lynch) and qualitative and quantitative pharmaceutical market analysis (Decision Resources). Kiran holds a first-class degree in Natural Sciences from Cambridge University and a PhD in Viral Mechanisms of Oncogenesis from Imperial College London.

    Download Slides

    Please login to download the slides

    Key Learning Objectives

    • Exploring novel R&D strategies to maximise revenue, decrease costs and mitigate risk in pharmaceuticals
    • The economics of orphan drugs; is the targeting of orphan diseases a profitable strategy?
    • Exploiting the growing number of failed drugs through repurposing efforts
    • Risk-sharing arrangements and financing deals as a means to mitigate developmental risk

    Audience

    • CSO
    • Chief Scientist
    • Head of R&D
    • VP R&D
    • Scientific Director
    • Director R&D
    • Group Leader Drug Discovery
    • Head of Drug Discovery
    • Leaders of Chemistry Head of Biology / Pharmacology Head of Discovery Technologies
    • Head of Translational Research
    • Group Leader
    • Portfolio Manager
    • R&D Strategist
    • Senior Scientist
    • Medicinal Chemist
    • Biologist